ArticleOncotarget2017

Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with

Kohei Shitara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.